What is Supernus Pharmaceuticals Inc Quarterly Revenue?

Supernus Pharmaceuticals Inc Quarterly Revenue Supernus Pharma Inc Jun-2026 Quarterly Revenue is $219 Million which is growth of 32.4% YoY.

What is Supernus Pharmaceuticals Inc Quarterly Net Profit?

Supernus Pharmaceuticals Inc Quarterly Net Profit Supernus Pharma Inc Jun-2026 Quarterly Net Profit is $-58 Million which is growth of -359.4% YoY.

What is Supernus Pharmaceuticals Inc Annual Revenue?

Supernus Pharmaceuticals Inc Annual Revenue Supernus Pharma Inc Dec-2025 Annual Revenue is $719 Million which is growth of 8.6% YoY.

What is Supernus Pharmaceuticals Inc Annual Net Profit?

Supernus Pharmaceuticals Inc Annual Net Profit Supernus Pharma Inc Dec-2025 Annual Net Profit is $-39 Million which is growth of -152.2% YoY.

What is Supernus Pharmaceuticals Inc Total Shareholders Fund?

Supernus Pharmaceuticals Inc Total Shareholders Fund Supernus Pharma Inc Dec-2025 Total Shareholders Fund is $1,062 Million which is growth of 2.5% YoY.

What is Supernus Pharmaceuticals Inc Total Assets?

Supernus Pharmaceuticals Inc Total Assets Supernus Pharma Inc Dec-2025 Total Assets is $1,453 Million which is growth of 6.2% YoY.

What is Supernus Pharmaceuticals Inc Book Value Per Share?

Supernus Pharmaceuticals Inc Book Value Per Share Supernus Pharma Inc Book Value Per Share is $18 which is growth of -6.6% YoY.

What is Supernus Pharmaceuticals Inc ROE?

Supernus Pharmaceuticals Inc ROE Supernus Pharma Inc ROE is 0% which is growth of 0% YoY.

What is Supernus Pharmaceuticals Inc Cash From Operating Activity?

Supernus Pharmaceuticals Inc Cash From Operating Activity Supernus Pharma Inc Dec-2025 Cash From Operating Activity is $47 Million which is growth of -72.5% YoY.

What is Supernus Pharmaceuticals Inc Net Cash Flow?

Supernus Pharmaceuticals Inc Net Cash Flow Supernus Pharma Inc Dec-2025 Net Cash Flow is $61 Million which is growth of 1158.3% YoY.

SUPN quarterly and annual earnings report: results, revenue, profit, P&L, balance sheet, cash flow, financial ratios, revenue mix, peer comparison, and financial documents

View Charts

Forecaster Analyst Estimates for SUPN share price target, revenues, EPS, net income and more

SUPN quarterly results: revenue, profit, and P&L – 13 quarter history

Nested row level

Base Level

Reporting Type

Originally Reported

Cell Data

Actual

Table Settings

YoY & New to Old

Nested row level

Base Level

Export

POSITIVE
Quarterly Revenue Supernus Pharma Inc Jun-2026 Quarterly Revenue is $219 Million which is growth of 32.4% YoY.
NEGATIVE
Quarterly Net Profit Supernus Pharma Inc Jun-2026 Quarterly Net Profit is $-58 Million which is growth of -359.4% YoY.

Supernus Pharmaceuticals Inc, Earnings Report - Quarterly Results, standalone, All financials are in USD Million and price data in USD
Indicator	Jun '26	Mar '26	Dec '25	Sep '25	Jun '25	Mar '25	Dec '24	Sep '24	Jun '24	Mar '24	Dec '23	Sep '23	Jun '23
SR_Q Operating Rev.	219.1	207.7	211.6	192.1	165.5	149.8	174.2	175.7	168.3	143.6	164.3	153.9	135.6
CostOfRevenue_Q Cost Of Rev.	33.7	23.4	23	19	16.8	15.8	26.1	17.6	17.9	16.3	19.6	19.6	21.1
GrossProfit_Q Gross Profit	185.4	184.3	188.6	173.1	148.6	134.1	148.1	158.1	150.4	127.3	144.7	134.3	114.5
OEXPNS_Q Operating Exp. ⌄	188.4	190.3	174.7	233.4	136.5	136.7	126.3	118.3	132.2	131.6	125.7	126.6	131.3
AdminAndSellingExpenses_Q Admin Plus Selling Exp.	133.6	125.2	122.4	179.7	93.6	89.9	79.4	69.8	85.9	86.5	81.3	82.7	86.8
ResearchAndDevlopmentExpenses_Q RnD Exp.	29.5	39.4	27.8	29.4	22.1	26.9	28.7	29	26.2	24.9	23.4	22.7	24.4
OP_Q Operating Profit	-3	-5.9	13.8	-60.2	12.1	-2.6	21.8	39.8	18.2	-4.3	19	7.7	-16.8
NetNonOperIntIncExp_Q Net Non Operations Interest Incuding Expenses ⌄	0.3	2.4	2	2.3	4.5	4.4	5	4.1	3.7	3.4	2	1.8	0.5
Others_Q Other Interest Earned	2.6	2.4	2	2.3	4.5	4.4	5	4.1	3.7	3.4	2	1.8	1.4
IntExpNonOperating_Q Interest Exp. Non Operating	2.3	-	-	-	-	-							0.9
PBT_Q Profit Before Tax	-57.7	-6	-1.9	-58	16.7	-5.8	26.4	44.9	26.3	0.2	1	9.9	-17.1
TAX_Q Tax	0.7	-3.7	2.2	-12.8	-5.8	6	11.1	6.5	6.4	0.1	-0.2	25.9	-16.3
NICommonStockholders_Q Net Income Common Stockholders ⌄	-58.4	-2.3	-4.1	-45.1	22.5	-11.8	15.3	38.5	19.9	0.1	1.2	-16	-0.8
NP_Q Net Profit	-58.4	-2.3	-4.1	-45.1	22.5	-11.8	15.3	38.5	19.9	0.1	1.2	-16	-0.8
NIIncludingNoncontrollingInterests_Q Net Income Including Non controlling Interests	-58.4	-2.3	-4.1	-45.1	22.5	-11.8	15.3	38.5	19.9	0.1	1.2	-16	-0.8
DilutedNIAvailtoComStockholders_Q Diluted NI Avail to Com Stockholders Ann.	-58.4	-2.3	-4.1	-45.1	22.5	-11.8	15.3	38.5	19.9	0.1	1.2	-16	-0.8
EPS_Q Basic EPS	-1	-0	-0.1	-0.8	0.4	-0.2	0.3	0.7	0.4		0	-0.3	-0
AfterDilutedEPS_Q Diluted EPS After ExtraOrdinary	-0.4	-0	0.2	-0.8	0.4	-0.1	0.3	0.7	0.3	-0	0.3	-0.3	-0
SHARE_Q Number Of Shares End	58.1	57.7	57.4	56.6	56	55.9	55.5	55.2	55	54.8	54.7	54.6	54.5
NIContinuingDiscontinuedOper_Q Net Income Continuing Discontinued Operations	-58.4	-2.3	-4.1	-45.1	22.5	-11.8	15.3	38.5	19.9	0.1	1.2	-16	-0.8
NormalizedIncome_Q Normalized Income	-25.4	-0.9	9.1	-45.1	22.5	-6.1	15.6	37.6	16.6	-0.7	16	-16.3	-0.2
InterestIncome_Q Interest Income	2.6	2.4	2	2.3	4.5	4.4	5	4.1	3.7	3.4	2	1.8	1.4
INT_Q Interest	2.3	-	-	-	-	-							0.9
NetInterestIncome_Q Net Interest Income	0.3	2.4	2	2.3	4.5	4.4	5	4.1	3.7	3.4	2	1.8	0.5
EBIT_Q EBIT	-55.3	-5.9	1.7	-60.2	12.1	-2.6	26.4	44.9	26.3	0.2	1	9.9	-16.2
EBITDA_Q EBITDA	-29.6	20.2	26.7	-35.4	33.5	17.8	45.2	65.1	47	21	22.7	31.8	4.5
ReconciledCostOfRevenue_Q Reconciled Cost Of Rev.	33.3	22.9	22.5	18.5	16.3	15.2	25.5	17	17.3	15.7	19	19	20.5
ReconciledDepreciation_Q Reconciled Depr.	25.8	26.1	25	24.8	21.4	20.4	18.8	20.1	20.7	20.8	21.7	21.9	20.7
ProfitLossFromContinuingOperations_Q Profit From Continuing Operations	-58.4	-2.3	-4.1	-45.1	22.5	-11.8	15.3	38.5	19.9	0.1	1.2	-16	-0.8
NormalizedEBITDA_Q Normalized EBITDA	25.3	22.6	44.4	-35.4	33.5	25.5	45.6	64	42.7	19.9	42.7	31.3	5.3

*All financials are in USD Million and price data in USD

Add metric to table

Search...

SUPN competitor comparison and performance snapshot within industry

SUPN annual results: revenue, profit, P&L, and margins as of Dec 2025 – 11 year history

Nested row level

Base Level

Reporting Type

Originally Reported

Cell Data

Actual

Table Settings

YoY & New to Old

CAGR Columns

Select...

Nested row level

Base Level

Export

POSITIVE
Annual Revenue Supernus Pharma Inc Dec-2025 Annual Revenue is $719 Million which is growth of 8.6% YoY.
NEGATIVE
Annual Net Profit Supernus Pharma Inc Dec-2025 Annual Net Profit is $-39 Million which is growth of -152.2% YoY.

Supernus Pharmaceuticals Inc, Earnings Report - Annual Results, standalone, All financials are in USD Million and price data in USD
Indicator	CAGR 3 Yrs	CAGR 5 Yrs	TTM	Dec '25	Dec '24	Dec '23	Dec '22	Dec '21	Dec '20	Dec '19	Dec '18	Dec '17	Dec '16	Dec '15
SR_A Total Rev. Ann. ⌄	2.5%	6.7%		719	661.8	607.5	667.2	579.8	520.4	392.8	408.9	302.2	215	144.4
TotalOperatingRevenues_A Operating Rev. Ann.	2.5%	6.7%	830.4	719	661.8	607.5	667.2	579.8	520.4	392.8	408.9	302.2	215	144.4
CostOfRevenue_A Cost Of Rev. Ann.	-5.1%	7.3%	99	74.6	77.9	83.8	87.2	75.1	52.5	16.7	15.4	15.2	12	8.4
GrossProfit_A Gross Profit Ann.	3.6%	6.6%	731.4	644.4	583.9	523.7	580	504.7	467.9	376.1	393.5	287	203	136
OEXPNS_A Operating Exp. Ann.	8.4%	18.4%	786.8	681.3	508.4	510.3	534.4	425.2	292.3	227.5	249.1	187.5	148.8	118.3
OP_A Operating Profit Ann.	-	-	-55.4	-36.9	75.6	13.4	45.6	79.5	175.6	148.6	144.4	99.5	54.2	17.7
NetNonOperIntIncExp_A Net Non Operations Interest Incuding Expenses Ann, ⌄	-3.1%	-	7	13.3	16.2	8	14.6	-12.9	-5.1	-1.1	-4.3	1.3	-3.6	-0.6
Others_A Other Interest Earned Ann.	-15.1%	-6.6%	9.3	13.3	16.2	10.5	21.7	10.6	18.7	21.6	13.8	2.9	1.5	0.6
IntExpNonOperating_A Interest Exp. Non Operating Ann.	-	-				2.4	7.1	23.4	23.8	22.7	18.1	1.6	5.1	1.2
OtherExpenses_A Other Exp. Ann.	-	-		-25.4	6.1	-18.7	0.5	6.5	-1.9	-	-	-0.2	-0.2	-2.1
PBT_A PBT Ann.	-	-	-123.5	-49	97.9	2.8	60.7	73.2	168.7	147.5	140.2	100.6	50.4	15
TAX_A Tax Ann.	-	-	-13.6	-10.5	24	1.5	0	19.8	41.7	34.4	29.2	43.3	-40.9	1
NICommonStockholders_A Net Income Common Stockholders Ann. ⌄	-	-	-109.9	-38.6	73.9	1.3	60.7	53.4	127	113.1	111	57.3	91.2	14
NP_A Net Profit Ann.	-	-	-109.9	-38.6	73.9	1.3	60.7	53.4	127	113.1	111	57.3	91.2	14
NIIncludingNoncontrollingInterests_A Net Income Including Non controlling Interests Ann.	-	-	-109.9	-38.6	73.9	1.3	60.7	53.4	127	113.1	111	57.3	91.2	14
DilutedNIAvailtoComStockholders_A Diluted NI Avail to Com Stockholders Ann.	-	-	-109.9	-38.6	73.9	1.3	60.7	53.4	127	113.1	111	57.3	90.8	14
EPS_A EPS Ann.	-	-		-0.7	1.3	0	1.1	1	2.4	2.2	2.1	1.1	1.8	0.3
DilutedEPS_A Diluted EPS Ann.	-	-		-0.7	1.3	0	1	1	2.4	2.1	2.1	1.1	1.8	0.3
SHARE_Q Number Of Shares End	2%	1.7%		57.4	55.5	54.7	54.1	53.2	52.7	52.5	52.3	51.3	49.7	48.9
TotalExpenses_A Total Exp. Ann.	6.7%	17%		755.8	586.3	594.1	621.6	500.3	344.8	244.2	264.5	202.7	160.8	126.8
NIContinuingDiscontinuedOper_A Net Income Continuing Discontinued Operations Ann.	-	-	-109.9	-38.6	73.9	1.3	60.7	53.4	127	113.1	111	57.3	91.2	14
NormalizedIncome_A Normalized Income Ann.	-	-	-62.3	-18.6	69.3	15.2	60.2	48.7	128.4	113.1	111	57.4	91.4	16
InterestIncome_A Interest Income Ann.	-15.1%	-6.6%	9.3	13.3	16.2	10.5	21.7	10.6	18.7	21.6	13.8	2.9	1.5	0.6
INT_A Interest Ann.	-	-				2.4	7.1	23.4	23.8	22.7	18.1	1.6	5.1	1.2
EBITDA_A EBITDA Ann.	-34.8%	-27.4%	-18.1	42.5	178.3	90	153.4	129.2	210.5	176.9	165.4	110.3	57.9	17.1
ReconciledCostOfRevenue_A Reconciled Cost Of Rev. Ann.	-4.9%	7.7%	97.2	72.5	75.5	81.3	84.3	72.5	50	16.7	15.4	15.2	12	8.4
ReconciledDepreciation_A Reconciled Depr. Ann.	2.3%	38.3%	101.7	91.6	80.4	84.9	85.5	32.6	18.1	6.7	7.1	8.1	2.4	0.9
ProfitLossFromContinuingOperations_A Profit From Continuing Operations Ann.	-	-	-109.9	-38.6	73.9	1.3	60.7	53.4	127	113.1	111	57.3	91.2	14
NormalizedEBITDA_A Normalized EBITDA Ann.	-23.7%	-20.4%	56.9	68	172.2	108.7	152.9	122.7	212.4	176.9	165.4	110.5	58.1	19.3

*All financials are in USD Million and price data in USD

Add metric to table

Search...

Total Rev. Ann.

1Y CHG

8.6%

2Y CAGR

8.8%

3Y CAGR

2.5%

5Y CAGR

6.7%

7Y CAGR

8.4%

10Y CAGR

17.4%

Total Revenue Annual growth is higher than historical averages.

Operating Exp. Ann.

1Y CHG

34%

2Y CAGR

15.5%

3Y CAGR

8.4%

5Y CAGR

18.4%

7Y CAGR

15.5%

10Y CAGR

19.1%

Operating Expenses Annual Cr growth is higher than historical averages.

SUPN balance sheet as of Dec 2025: assets, liabilities, reserves, and borrowings – 11 year history

Nested row level

Base Level

Reporting Type

Originally Reported

Cell Data

Actual

Table Settings

YoY & New to Old

CAGR Columns

Select...

Nested row level

Base Level

Export

POSITIVE
Total Shareholders Fund Supernus Pharma Inc Dec-2025 Total Shareholders Fund is $1,062 Million which is growth of 2.5% YoY.
POSITIVE
Total Assets Supernus Pharma Inc Dec-2025 Total Assets is $1,453 Million which is growth of 6.2% YoY.

Supernus Pharmaceuticals Inc, Balance Sheet, standalone, All financials are in USD Million and price data in USD
Indicator	CAGR 3 Yrs	CAGR 5 Yrs	Dec '25	Dec '24	Dec '23	Dec '22	Dec '21	Dec '20	Dec '19	Dec '18	Dec '17	Dec '16	Dec '15
TA_A Total Assets Ann. ⌄	-5.2%	-0.7%	1,452.7	1,368.1	1,277.7	1,702.5	1,689.2	1,504.1	1,160.3	977.8	424.5	309.6	188.7
CA_A Total Current Assets Ann.	-4.3%	0.4%	644.2	686.1	493.1	734.2	601.6	630.4	472.6	493.5	228.5	151.4	106
CashEquivalentsShortTermInvestments_A Cash Equivalents and Short Term Investments Ann.	-12.5%	-6.1%	308.7	453.6	254.9	461.3	339.7	422.5	347.1	356	140	90.1	62.2
Receivables_A Change In Account Receivables Ann.	4.3%	5.9%	187.8	142.1	144.2	165.5	148.9	140.9	87.3	102.9	65.6	41.5	25.9
Inventories_A Inventories Ann.	-3.4%	11.3%	82.4	54.3	77.4	91.5	86	48.3	26.6	25.7	16.3	16.8	12.6
OtherCurrentAssets_A Other Current Assets Ann.	60.5%	28.4%	65.3	36.1	16.7	15.8	27	18.7	11.6	8.9	6.5	3	5.3
TotalNonCurrentAssets_A Total Non Current Assets Ann.	-5.8%	-1.5%	808.5	682	784.6	968.4	1,087.6	873.7	687.6	484.3	196	158.2	82.8
NetPPE_A Net PPE Ann.	-11.6%	-22.6%	10.5	11.5	13.5	15.2	17	37.8	38.4	4.1	5.1	4.3	3.9
InvestmentsAndAdvances_A Investments & Advances Ann.	-	-	-		16.6	93.9	119.2	350.4	591.8	418.8	133.6	75.4	55
OtherNonCurrentAssets_A Other Non Current Assets Ann.	17.9%	8.6%	65.3	31.5	37.5	39.8	49.2	43.3	0.6	0.4	0.4	0.3	0.4
TotalLiabilitiesNetMinorityInterest_A Total Liabilities Net Minority Interest Ann. ⌄	-21.8%	-12.4%	390.9	332.3	356.2	816.3	873.3	759.2	564.9	524.8	157	117.8	69.9
CL_A Total Current Liabilities Ann.	-21.1%	6.7%	338.2	292.4	290.2	688	315.4	245.1	160.6	161.4	123	80.7	56.1
PayablesAndAccruedExpenses_A Payables & Accrued Exp.s Ann.	0.7%	4.3%	228.8	216.9	204.8	224.3	215.9	185.4	143.3	145.6	108.2	68.3	48.4
CurrentDebtCapLeaseObligation_A Current Debt Cap Lease Obligation Ann.	-70.4%	22.8%	10.6	6.9	8.3	408.8	6.5	3.8	2.8	-	-	-	-
CurrentDeferredLiabilities_Q Current Deferred Liabilities	-	-	-	-	-	-	-	-	-		0.3	0.2	0.2
OtherCurrentLiabilities_A Other Current Liabilities Ann.	22.2%	11.6%	69.3	47.3	56.4	38	65	40	3.2	2.2	4.3	3.1	-
TotalNonCurrentLiabilities_A Total Non Current Liabilities Ann.	-25.6%	-36.6%	52.8	39.9	66	128.4	557.9	514.1	404.3	363.4	34	37.1	13.8
LongTermDebtAndCapitalLeaseObligation_Q LT Debt & Capital Lease Obligation	-5.5%	-40.6%	30.4	27.4	33.2	36	420.6	410.6	375.6	329.5	-	4.2	7.2
TradeandOtherPayablesNonCurrent_A Trade & Other Payables Non Current Ann.	-	-	-	-	-	-	-	-	-	-	-	-	-
TotalDeferredCreditsAndOtherNonCurrentLiabilities_A Total Deferred Credits & Other Non Current Liabilities Ann.	-	-	-	-	-	-	-	-	-	-	-	-	-
TotalShareHoldersFunds_A Total ShareHolders Funds Ann. ⌄	6.2%	7.3%	1,061.7	1,035.7	921.5	886.2	815.9	744.9	595.4	453	267.5	191.8	118.9
EQCAP_A Equity Share Capital Ann.	6.2%	7.3%	1,061.7	1,035.7	921.5	886.2	815.9	744.9	595.4	453	267.5	191.8	118.9
CapitalStock_A Capital Stock Ann.	0%	0%	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
RetainedEarnings_A Retained Earnings Ann.	2.5%	9.7%	517.9	556.4	482.6	481.3	379.9	326.5	199.6	86.5	-26.8	-84.3	-144.6
GainsLossesNotAffectingRetainedEarnings_A Gains Losses Not Affecting Retained Earnings Ann.	-	-	-0	-0.2	-0.6	-3.2	1.5	9	7.4	-3.2	-0.8	-0.1	-0.5
TotalCapitalization_A Total Capitalization Ann.	6.2%	-0.8%	1,061.7	1,035.7	921.5	886.2	1,195.1	1,106.6	940.6	782.5	267.5	195.9	126.1
TangibleAssets_A Tangible Assets Ann.	76.6%	4%	367.4	396.8	204.6	66.7	-86.4	302.6	570.6	421.7	231.5	175.3	117.9
WC_A Working Capital Ann.	87.8%	-4.5%	306	393.7	202.9	46.2	286.2	385.3	312.1	332.1	105.5	70.7	49.9
InvestedCapital_A Invested Capital Ann.	-6.2%	-0.8%	1,061.7	1,035.7	921.5	1,288.2	1,195.1	1,106.6	940.6	782.5	267.5	195.9	126.1
TangibleBookValue_A Tangible Book Value Ann.	76.6%	4%	367.4	396.8	204.6	66.7	-86.4	302.6	570.6	421.7	231.5	175.3	117.9
Borrowings_A Borrowings Ann.	-54.8%	-37%	41	34.3	41.5	444.8	427	414.3	378.4	329.5	-	4.2	7.2
NetDebt_A Net Debt Ann.	-	-	-	-	-	308.9	175.8	73.1	163.8	137.2	-	-	-
ShareIssued_A Share Issued Ann.	1.9%	1.7%	57.5	55.7	54.7	54.3	53.3	52.9	52.5	52.3	51.3	50	49
SHARE_Q Number Of Shares End	2%	1.7%	57.4	55.5	54.7	54.1	53.2	52.7	52.5	52.3	51.3	49.7	48.9

*All financials are in USD Million and price data in USD

Add metric to table

Search...

Total Assets Ann.

1Y CHG

6.2%

2Y CAGR

6.6%

3Y CAGR

-5.2%

5Y CAGR

-0.7%

7Y CAGR

5.8%

10Y CAGR

22.6%

Total Assets Annual growth is higher than historical averages.

Total Current Liabilities Ann.

1Y CHG

15.7%

2Y CAGR

3Y CAGR

-21.1%

5Y CAGR

6.7%

7Y CAGR

11.1%

10Y CAGR

19.7%

Total Current Liabilities Annual Cr growth is higher than historical averages.

Total ShareHolders Funds Ann.

1Y CHG

2.5%

2Y CAGR

7.3%

3Y CAGR

6.2%

5Y CAGR

7.3%

7Y CAGR

12.9%

10Y CAGR

24.5%

Total ShareHolders Funds Annual growth is lower than historical averages.

SUPN ROE, ROCE, book value, and debt-to-equity ratio as of Dec 2025 – 11 year history

Nested row level

Base Level

Reporting Type

Originally Reported

Cell Data

Actual

Table Settings

YoY & New to Old

CAGR Columns

Select...

Nested row level

Base Level

Export

NEGATIVE
Book Value Per Share Supernus Pharma Inc Book Value Per Share is $18 which is growth of -6.6% YoY.
NEUTRAL
ROE Supernus Pharma Inc ROE is 0% which is growth of 0% YoY.

Supernus Pharmaceuticals Inc, Ratios, standalone, All financials are in USD Million and price data in USD
Indicator	CAGR 3 Yrs	CAGR 5 Yrs	Dec '25	Dec '24	Dec '23	Dec '22	Dec '21	Dec '20	Dec '19	Dec '18	Dec '17	Dec '16	Dec '15
ROA_A RoA Ann. %	-	-	-	5.58%	0.09%	3.58%	3.35%	9.53%	10.58%	15.83%	15.61%	36.61%	8.59%
ROE_A ROE Ann. %	-	-	-	7.55%	0.15%	7.13%	6.85%	18.94%	21.57%	30.81%	24.95%	58.73%	14.74%
ROIC_Q ROIC %	-	-	-	1.1	-0	1.9	0.4	2.7	3.5	3.5	5.1	7.9	5.6
OPMPCT_A OPM Ann. %	-	-	-5.13%	11.42%	2.21%	6.84%	13.71%	33.74%	37.83%	35.33%	32.93%	25.22%	12.23%
NBTO_A Inventory Turnover Ratio Ann.	-	-	-	1.2	1	1	1.1	1.4	0.6	0.7	0.9	0.8	0.7
ASETTO_A Asset Turnover Ann. %	-	-	-	0.5	0.4	0.4	0.4	0.4	0.4	0.6	0.8	0.9	0.9
WCTO_A Working Capital Turnover Ann.	-45%	11.4%	2.4	1.7	3	14.4	2	1.4	1.3	1.2	2.9	3	2.9
QuickRatio_A Quick Ratio Ann.	-	-	-	2	1.4	0.9	1.6	2.3	2.7	2.8	1.7	1.6	1.6
CRATIO_A Current Ratio Ann.	-	-	-	2.4	1.7	1.1	1.9	2.6	2.9	3.1	1.9	1.9	1.9
IC_A Interest Coverage Ratio Ann.	-	-	-	-	2.2	9.6	4.1	8.1	7.5	8.7	65.2	10.9	13.2
LTDE_A LT Debt To Equity Ann.	-	-	-	0	0	0	0.5	0.6	0.6	0.7	-	0	0.1

*All financials are in USD Million and price data in USD

Add metric to table

Search...

SUPN cash flow: net, operating, investing, and financing flows as of Dec 2025 – 11 year history

Nested row level

Base Level

Reporting Type

Originally Reported

Cell Data

Actual

Table Settings

YoY & New to Old

CAGR Columns

Select...

Nested row level

Base Level

Export

NEGATIVE
Cash From Operating Activity Supernus Pharma Inc Dec-2025 Cash From Operating Activity is $47 Million which is growth of -72.5% YoY.
POSITIVE
Net Cash Flow Supernus Pharma Inc Dec-2025 Net Cash Flow is $61 Million which is growth of 1158.3% YoY.

Supernus Pharmaceuticals Inc, Cash Flow, standalone, All financials are in USD Million and price data in USD
Indicator	CAGR 3 Yrs	CAGR 5 Yrs	Dec '25	Dec '24	Dec '23	Dec '22	Dec '21	Dec '20	Dec '19	Dec '18	Dec '17	Dec '16	Dec '15
CFO_A Cash from Operating Act. Ann. ⌄	-26%	-19.3%	47.3	172	111.1	116.8	127.1	138.4	143.1	129	114.6	66.8	32.1
ProfitLossFromContinuingOperations_A Profit From Continuing Operations Ann.	-	-	-38.6	73.9	1.3	60.7	53.4	127	113.1	111	57.3	91.2	14
DepreciationAmortizationDepletion_A Depreciation Amortization Depletion Ann.	2.3%	38.3%	91.6	80.4	84.9	85.5	32.6	18.1	6.7	7.1	8.1	2.4	0.9
DepreciationAndAmortization_A Depreciation And Amortization Ann.	2.3%	38.3%	91.6	80.4	84.9	85.5	32.6	18.1	6.7	7.1	8.1	2.4	0.9
DeferredTax_A Deferred Tax Ann.	-	54%	5.2	-20.1	-25.7	-26.3	-5	0.6	-5.8	-4.2	21.2	-41.8	-
DeferredIncomeTax_A Deferred Income Tax Ann.	-	54%	5.2	-20.1	-25.7	-26.3	-5	0.6	-5.8	-4.2	21.2	-41.8	-
EmployeesStockOptions_A ESOPs Ann.	23.4%	14.8%	33.1	27.8	26.8	17.6	17.9	16.6	14.9	11.3	8.4	5.9	4.2
OtherNonCashItems_A Other Non Cash Items Ann.	323.6%	8.8%	30.4	1.4	12.9	0.4	24.6	19.9	18.1	10.2	-3.8	0.4	0.8
ChangeInWorkingCapital_A Change In Working Capital Ann.	-	-	-75.2	-2.1	-9.1	-24.2	3.6	-36.5	0.6	-4.7	23.7	8.5	10.1
ChangeInReceivables_A Change In Receivables Ann.	-	-	-22.3	2.1	18.8	-16.4	3.9	-34.6	15.8	-35.9	-24.1	-15.6	-8.6
ChangeInInventory_A Change In Inventory Ann.	-	-	-7.5	15.8	6.1	-17.9	-14.6	-10.1	-1	-9.4	0.5	-4.2	0.9
ChangePayablesAccruedExpense_A Change Payables Accrued Expense Ann.	-	-	-32.2	-0.6	-33.7	-0.2	22.7	18.7	-6.2	42	44.6	26.2	18.8
ChangeInOtherCurrentAssets_A Change In Other Current Assets Ann.	-	-	-	-	-	-	-	-	-	-	-	-	-
ChangeInOtherCurrentLiabilities_A Change In Other Current Liabilities Ann.	-	-	-	-		-2.1	-	-	-	-	-	-	-
ChangeInOtherWorkingCapital_A Change In Other Working Capital Ann.	-	-	-	-	-	-	-	-	-5.2	0.8	6.2	-0.2	0.6
CFI_A Cash from Investing Act. Ann. ⌄	-	-	4.1	-189.9	268.7	-216.7	-81.9	-34.7	-157.9	-413.5	-86.4	-36	-36.2
NetPPEPurchaseAndSale_A Net PPE Purchase & Sale Ann.	-	-	-1.3	-0.7	-0.6	-0.4	-2	-3.5	-2.7	-0.8	-2	-1.6	-2.1
PurchaseOfPPE_A Purchase Of PPE Ann.	-	-	-1.3	-0.7	-0.6	-0.4	-2	-3.5	-2.7	-0.8	-2	-1.6	-2.1
NetBusinessPurchaseAndSale_A Net Business Purchase & Sale Ann.	-	-	-293.1	-			-311.7	-313.5	-	-	-	-	-
PurchaseOfBusiness_A Purchase Of Business Ann.	-	-	-293.1	-			-311.7	-313.5	-	-	-	-	-
PurchaseOfInvestment_A Purchase Of Investment Ann.	-	-	-475.9	-688	-101.6	-407	-311.6	-95.9	-409.7	-491.7	-101.9	-47.4	-63.2
SaleOfInvestment_A Sale Of Investment Ann.	59.5%	15.4%	774.5	498.9	370.9	190.7	530.5	378.4	253.2	79.8	28.7	31.8	37.6
NetOtherInvestingChanges_A Net Other Investing Changes Ann.	-	-	-	-	-	-	-	-0.2	1.4	-0.8	-11.2	-18.8	-8.5
CFA_A Cash from Financing Act. Ann. ⌄	-	20.4%	9.1	12.2	-397.9	-10.5	-130.4	3.6	3.9	376.4	5.7	2.1	1.9
NetIssuancePaymentsOfDebt_A Net Issuance Payments Of Debt Ann.	-	-			-402.5		-137.5	-0.8		402.5	-	-
NetLongTermDebtIssuance_A Net Long Term Debt Issuance Ann.	-	-					-137.5	-0.8		402.5	-	-
NetShortTermDebtIssuance_A Net ST Debt Issuance Ann.	-	-	-	-	-402.5	-	-	-	-	-	-	-	-
NetCommonStockIssuance_A Net Common Stock Issuance Ann.	44.7%	53.6%	37.6	14.9	6.6	12.4	7.1	4.4	3.9	11.6	5.7	2.1	1.9
CommonStockIssuance_A Common Stock Issuance Ann.	44.7%	53.6%	37.6	14.9	6.6	12.4	7.1	4.4	3.9	11.6	5.7	2.1	1.9
CommonStockPayments_A Common Stock Payments Ann.	-	-	-	-	-	-	-	-	-	-	-	-	-
dividend_1Y_actual Dividend 1year	-	-
DividendPerShare_A Dividend Per Share Ann.	-	-	-	-	-	-	-	-	-	-	-	-	-
NetOtherFinancingCharges_A Net Other Financing Charges Ann.	-	-	-28.5	-2.7	-2	-22.9	-	-	-	-10.4	-	-	-
CashAndCashEquivalentEndOfYear_A Cash Plus Cash Eqv. End Of Year Ann.	11.7%	-14.8%	129.9	69.3	75.1	93.1	203.4	288.6	181.4	192.3	100.3	66.4	34.2
NetIncDecInCashAndCashEquivalents_A Net Increase In Cash Plus Cash Eqv.s Ann.	-	-10.8%	60.6	-5.7	-18.1	-110.3	-85.2	107.3	-10.9	91.9	33.9	32.9	-2.2
CashAndCashEquivalentBeginOfYear_A Cash Plus Cash Eqv. Begin Of Year Ann.	-30.2%	-17.5%	69.3	75.1	93.1	203.4	288.6	181.4	192.3	100.3	66.4	33.5	36.4
IncomeTaxPaidSupplementalData_A Income Tax Paid Supplemental Data Ann.	-0.2%	-18.7%	16.1	53.3	36.6	16.2	25.2	45.4	51.5	34.8	-	-	-
InterestPaidSupplementalData_A Interest Paid Supplemental Data Ann.	-	-			2	2.5	2.5	2.5	2.5	1.3	1.7	0.5	0.8
CapitalExpenditure_A Capex Ann.	-	-	-1.3	-0.7	-0.6	-0.4	-2	-3.5	-2.7	-0.8	-2	-1.6	-2.1
IssuanceOfCapitalStock_A Issuance Of Capital Stock Ann.	44.7%	53.6%	37.6	14.9	6.6	12.4	7.1	4.4	3.9	11.6	5.7	2.1	1.9
IssuanceOfDebt_A Issuance Of Debt Ann.	-	-			93		0.8			402.5	-	-	-
RepaymentOfDebt_A Repayment Of Debt Ann.	-	-			-495.5		-138.3	-0.8	-	-	-	-
RepurchaseOfCapitalStock_A Repurchase Of Capital Stock Ann.	-	-	-	-	-	-	-	-	-	-	-	-	-
FreeCashFlow_A Free Cash Flow Ann.	-26.6%	-19.4%	46	171.2	110.5	116.4	125.1	135	140.4	128.1	112.6	65.2	30

*All financials are in USD Million and price data in USD

Add metric to table

Search...

Cash from Operating Act. Ann.

1Y CHG

-72.5%

2Y CAGR

-34.8%

3Y CAGR

-26%

5Y CAGR

-19.3%

7Y CAGR

-13.4%

10Y CAGR

Cash from Operating Activity Annual is falling faster than historical averages.

Cash from Investing Act. Ann.

2Y CAGR

-87.6%

Cash from Investing Activity Annual growth is lower than historical averages.

Cash from Financing Act. Ann.

1Y CHG

-25.4%

5Y CAGR

20.4%

7Y CAGR

-41.2%

10Y CAGR

17%

Cash from Financing Annual Activity is falling faster than historical averages.

Forecaster
Quarterly
Competitors/Peers
Annual
Balance Sheet
Ratios
Cash Flow

SUPN quarterly and annual earnings report: results, revenue, profit, P&L, balance sheet, cash flow, financial ratios, revenue mix, peer comparison, and financial documents

SUPN - Forecaster

Forecaster Analyst Estimates for SUPN share price target, revenues, EPS, net income and more

SUPN - Earnings Report - Quarterly Results

SUPN quarterly results: revenue, profit, and P&L – 13 quarter history

Quarterly Revenue Supernus Pharma Inc Jun-2026 Quarterly Revenue is $219 Million which is growth of 32.4% YoY.

Quarterly Net Profit Supernus Pharma Inc Jun-2026 Quarterly Net Profit is $-58 Million which is growth of -359.4% YoY.

SUPN - Competitors/Peers

SUPN competitor comparison and performance snapshot within industry

SUPN - Earnings Report - Annual Results

SUPN annual results: revenue, profit, P&L, and margins as of Dec 2025 – 11 year history

Annual Revenue Supernus Pharma Inc Dec-2025 Annual Revenue is $719 Million which is growth of 8.6% YoY.

Annual Net Profit Supernus Pharma Inc Dec-2025 Annual Net Profit is $-39 Million which is growth of -152.2% YoY.

SUPN - Balance Sheet

SUPN balance sheet as of Dec 2025: assets, liabilities, reserves, and borrowings – 11 year history

Total Shareholders Fund Supernus Pharma Inc Dec-2025 Total Shareholders Fund is $1,062 Million which is growth of 2.5% YoY.

Total Assets Supernus Pharma Inc Dec-2025 Total Assets is $1,453 Million which is growth of 6.2% YoY.

SUPN - Ratios

SUPN ROE, ROCE, book value, and debt-to-equity ratio as of Dec 2025 – 11 year history

Book Value Per Share Supernus Pharma Inc Book Value Per Share is $18 which is growth of -6.6% YoY.

ROE Supernus Pharma Inc ROE is 0% which is growth of 0% YoY.

SUPN - Cash Flow

SUPN cash flow: net, operating, investing, and financing flows as of Dec 2025 – 11 year history

Cash From Operating Activity Supernus Pharma Inc Dec-2025 Cash From Operating Activity is $47 Million which is growth of -72.5% YoY.

Net Cash Flow Supernus Pharma Inc Dec-2025 Net Cash Flow is $61 Million which is growth of 1158.3% YoY.